Skip to main content
  • Home
  •  Incorporating GDMT and PRO Endpoints for Personalised Heart Failure Management

Incorporating GDMT and PRO Endpoints for Personalised Heart Failure Management

Topic:
  • Heart Failure

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

Incorporating GDMT and PRO Endpoints for Personalised HF Management
No ratings

Overview

This series of peer-to-peer discussions examines the practicalities of personalising heart failure management in the context of recent changes to international clinical practice guidelines.

 

At this exciting juncture, we now have two SGLT-2 inhibitors that offer clinical benefit across the spectrum of ejection fraction, and an increasing body of real-world and registry-based data showing the clear benefit of early guideline directed medical therapy (GDMT) adoption. In addition, there is a clear move towards the use of patient reported outcomes (PROs) in addition to clinical endpoints. But how can we start to incorporate these changes in current practice?

 

In this series, our specially selected faculty of experts consider how we can be using these recent developments to personalise our management approach to heart failure and why it matters for better long-term patient outcomes.

Support Statement

This programme is supported by an unrestricted educational grant from AstraZeneca.

Disclosure

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

The session, ‘Incorporating GDMT and PRO Endpoints for Personalised Heart Failure Management' is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits. 

 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Instruction to Participants

There is no fee for taking part in this online learning activity.

 

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

 

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

  • Cardiologists
  • Heart Failure Specialists
  • Primary Care Physicians
  • Nurses, Pharmacists, and other Allied Healthcare Professionals

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Review current GDMT in HFrEF and HFpEF
  • Describe the relationship between initiation of GDMT and HF outcomes
  • Prescribe GDMT according to current international recommendations
  • Recall the elements of the Kansas City Cardiomyopathy Questionnaire
  • Describe the clinical studies that support the use of functional and QoL measures in practice
  • Initiate quality of life and functional improvement measures in routine practice
  • Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
  • Adopt shared decision-making with HF patients
Register now Log in

Module

Title

Duration

Speakers

Discussion Optimising Clinical Success With Foundational Heart Failure Treatment 15 mins Andrew JS Coats Mikhail Kosiborod
Discussion Personalising Your Approach to Heart Failure Treatment 15 mins Giuseppe Rosano Biykem Bozkurt
Discussion Adopting Patient Reported Outcomes in Heart Failure Management 15 mins Mikhail Kosiborod Shelley Zieroth
Discussion.

Optimising Clinical Success With Foundational Heart Failure Treatment

Duration: 15 mins

Speakers: Andrew JS Coats Mikhail Kosiborod

Discussion.

Personalising Your Approach to Heart Failure Treatment

Duration: 15 mins

Speakers: Giuseppe Rosano Biykem Bozkurt

Discussion.

Adopting Patient Reported Outcomes in Heart Failure Management

Duration: 15 mins

Speakers: Mikhail Kosiborod Shelley Zieroth

Speaker

Andrew JS Coats

Heart Research Institute, NSW, AU

Prof Coats is Editor-in-Chief of the Cardiac Failure Review journal. He has published over 20 patents, more than 750 full research papers and more than 120,000 career citations and has a personal H-index of

View full profile

Mikhail Kosiborod

Saint Luke’s Mid America Heart Institute, Kansas City, US

Dr Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke's Health System, and Professor of Medicine at the University of Missouri-Kansas City, US.

View full profile

Shelley Zieroth

St Boniface Hospital, Winnipeg, CA

Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada.

View full profile

Giuseppe Rosano

St George’s University Medical School of London, UK

Giuseppe Rosano is Consultant Cardiologist and Professor of Cardiology at St George’s, University of London, UK where he is also the director of MSc Heart Failure.

View full profile

Biykem Bozkurt

Baylor College of Medicine, Texas, US

Dr Biykem Bozkurt is the Immediate Past President of the Heart Failure Society of America. Dr Bozkurt is a Professor of Medicine, an advanced heart failure and cardiac transplantation specialist, Medical Care Line Executive (Medicine Department Chair) at the DeBakey VA Medical Center; W.A.

View full profile
1.00 EBAC

Related Courses

Implementing Heart Failure Guidelines with Collaborative Care
  • Not accredited

Learning objectives

  • Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
  • Apply latest guideline recommendations to patient cases
  • Describe barriers preventing early initiation of GDMT
  • Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
  • Identify the importance of the nurse/cross-functional team
See more
The Advancing Management of Transthyretin Amyloidosis
  • 1.00 EBAC

Learning objectives

  • To differentiate ATTR phenotypes based on presenting signs and symptoms.
  • To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
  • To recall how to identify disease progression across ATTR-cm.
  • To describe the different disease modifying treatments for ATTR including novel agents.
See more
Overcoming the Challenges in Optimising GDMT in HF
  • Not accredited

Learning objectives

  • Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
  • Recognise barriers preventing the use of GDMT in current practice.
  • Identify strategies needed to drive implementation of GDMT in clinical practice.
See more
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1.00 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more
Changing Paradigms in Therapy to Unmet Needs
  • 1.00 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response 
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy 
  • Incorporate quality of life measures for assessing therapeutic efficacy in HF 
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice 
See more
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now
  • Not accredited

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more
Heart Failure Management in a Changing Paradigm
  • 1.00 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy
  • Incorporate quality of life measures for assessing therapeutic efficacy in HF
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice
See more